The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs
Rattachement africain : gb, us, Kenya, vn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the goal of eliminating lymphatic filariasis (LF) as a public health problem by 2020. Despite considerable progress, the current prevalence is around 60% of the 2000 figure, with the deadline looming a year away. Consequently, there is a continued need for investment in both the mass drug administration (MDA) and morbidity management programs, and this paper aims to demonstrate that need by estimating the health and economic burdens of LF prior to MDA programs starting in GPELF areas. METHODS: A previously developed model was used to estimate the numbers of individuals infected and individuals with symptomatic disease, along with the attributable number of disability-adjusted life years (DALYs). The economic burden was calculated by quantifying the costs incurred by the health-care system in managing clinical cases, the patients' out-of-pocket costs, and their productivity costs. RESULTS: Prior to the MDA program, approximately 129 million people were infected with LF, of which 43 million had clinical disease, corresponding to a DALY burden of 5.25 million. The average annual economic burden per chronic case was US $115, the majority of which resulted from productivity costs. The total economic burden of LF was estimated at US $5.8 billion annually. CONCLUSIONS: These results demonstrate the magnitude of the LF burden and highlight the continued need to support the GPELF. Patients with clinical disease bore the majority of the economic burden, but will not benefit much from the current MDA program, which is aimed at reducing transmission. This assessment further highlights the need to scale up morbidity management programs.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs
- Date Crossref
- 25/07/2019
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Oxford Nuffield Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
London Centre for Neglected Tropical Disease Research pays non établi dans la noticeStructure de recherche
-
Imperial College London London Centre for Neglected Tropical Disease Research pays non établi dans la noticeUniversité ou école supérieure
-
The Task Force for Global Health pays non établi dans la noticeOrganisation à but non lucratif
-
Kenya Medical Research Institute Nairobi, Kenya (code pays fourni par la source)Structure de recherche
-
Wellcome Trust pays non établi dans la noticeOrganisation à but non lucratif
-
GlaxoSmithKline (United Kingdom) pays non établi dans la noticeEntreprise
-
Oxford University Clinical Research Unit pays non établi dans la noticeStructure de recherche
-
School of Public Health Department of Infectious Disease Epidemiology pays non établi dans la noticeUniversité ou école supérieure
-
Neglected Tropical Diseases Support Center pays non établi dans la noticeInstitution
-
Global Health Programs pays non établi dans la noticeInstitution
Nuffield Department of Medicine — University of Oxford, London Centre for Neglected Tropical Disease Research et London Centre for Neglected Tropical Disease Research — Imperial College London, avec 8 autres affiliations. Pays d’affiliation : Kenya.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.